Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Quality in Sport

Cemiplimab in oncology: a review of the literature
  • Home
  • /
  • Cemiplimab in oncology: a review of the literature
  1. Home /
  2. Archives /
  3. Vol. 77 (2026) /
  4. Medical Sciences

Cemiplimab in oncology: a review of the literature

Authors

  • Alicja Piwowarczyk Independent Public Health Care Facility in Myślenice, ul. Szpitalna 2, 32-400 Myślenice https://orcid.org/0009-0005-8850-3925
  • Julia Białas District Hospital in Limanowa Name of the Divine Mercy, ul. Józefa Piłsudskiego 61, 34- 600 Limanowa, Poland https://orcid.org/0009-0008-5128-1611
  • Joanna Paluchowska Ludwik Rydygier SpecialistHospital in Kraków, Kraków, Poland https://orcid.org/0009-0002-7762-7410
  • Alicja Kodura Specialist Hospital Stefan Żeromski in Kraków, Osiedle na Skarpie 66, 31-913 Kraków, Poland https://orcid.org/0009-0004-8410-1673
  • Przemysław Piątek Father Rafał Hospital SPZOZ in Proszowice, Kopernika 13, 32-100 Proszowice, Poland https://orcid.org/0009-0000-8121-7647
  • Łukasz Szymański Frydrychowice Health Center Poland https://orcid.org/0009-0001-7172-9953
  • Milena Mordarska The University Hospital in Krakow, ul. Macieja Jakubowskiego 2, 30-688 Kraków, Poland https://orcid.org/0009-0002-3318-8006
  • Artur Merc Independent Public Health Care Facility in Myślenice, ul. Szpitalna 2, 32-400 Myślenice, Poland https://orcid.org/0009-0002-1651-018X
  • Jan Łozowski Gabriel Narutowicz Municipal Hospital in Kraków, ul. Prądnicka 35-37, 31-202 Kraków, Poland https://orcid.org/0009-0006-1355-0740

DOI:

https://doi.org/10.12775/QS.2026.77.75787

Keywords

cemiplimab, non-small cell lung cancer, cervical cancer, cutaneous squamous cell carcinoma, PD-1 receptor inhibitor

Abstract

Background.Cemiplimab, a fully human antibody that blocks programmed cell death 1 (PD-1), plays a key role in the treatment of patients with advanced cancers, including non-small cell lung cancer, cutaneous squamous cell carcinoma and cervical cancer, which typically have a poor prognosis under standard therapies.

Aim.The aim of this narrative review is to analyze the use of cemiplimab in the treatment of advanced cancers: non-small cell lung cancer, squamous cell carcinoma of the skin and cervical cancer.

Material and methods.A literature search was conducted in the PubMed and Google Scholar databases using the following keywords: "cemiplimab", "PD-1 receptor inhibitor", "non-small cell lung cancer", "cervical cancer", and "cutaneous squamous cell carcinoma". The review included original studies, systematic reviews and clinical trials without specific time restrictions. The reference lists of the retrieved articles were also cross-referenced to obtain additional valuable information.

Results.Current studies provide strong evidence supporting the efficacy of cemiplimab in the treatment of advanced cancers, including non-small cell lung cancer (NSCLC), cervical cancer and squamous cell skin cancer (CSCC).

Conclusions.Cemiplimab demonstrates significant clinical benefits in treating advanced cancers such as cervical cancer, non-small cell lung cancer (NSCLC) and squamous cell skin cancer (CSCC). Further clinical investigations are warranted to fully establish its therapeutic role in oncology.

References

1. LIBTAYO (cemiplimab-) injection, for intravenous use: full prescribing information [Internet] Initial U.S. Approval: 2018 Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761097s014lbl.pdf

2. Krishnansu S. Tewari, M.D., Bradley J. Monk, M.D., et al. Survival with Cemiplimab in Recurrent Cervical CancerN Engl J Med 2022;386:544-555Available from:https://doi.org/10.1056/NEJMoa2112187

3. Danny Rischin, M.D., Sandro Porceddu, M.D., Fiona Day, M.B., et al. Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell CarcinomaN Engl J Med. 2025;393:774-785 Available from: https://doi.org/10.1056/NEJMoa2502449.

4. Neil D. Gross, M.D. David M. Miller, et al. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaN Engl J Med 2022;387:1557-1568 Available from: https://doi.org/10.1056/NEJMoa2209813

5. Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trialNature Medicine volume 28, pages2374–2380 (2022) Available from: https://www.nature.com/articles/s41591-022-01977-y

6. Michael R. Migden, M.D., Danny Rischin, M.D., Chrysalyne D. Schmults et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaN Engl J Med 2018;379:341-351 Available from:https://doi.org/10.1056/NEJMoa1805131

7. Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingJ Immunother Cancer. 2020 Jun 17;8(1):e000775. Available from:https://doi.org/10.1136/jitc-2020-000775

8. Saadettin Kilickap MD a, Ana Baramidze PhD b, Ahmet Sezer MD c et al. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1Journal of Thoracic OncologyVolume 20, Issue 7, July 2025, Pages 941-954 Available from: https://doi.org/10.1016/j.jtho.2025.03.033

9. Danny Rischin a, Marta Gil-Martin b, Antonio González-Martin c 1et al. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancerGynecologic OncologyVolume 159, Issue 2, November 2020, Pages 322-328 Available from: https://doi.org/10.1016/j.ygyno.2020.08.026

10. Ana Oaknin a, Bradley J. Monk b, Andreia Cristina de Melo c, Hee Seung Kim d, Yong Man Kim eCemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trialEuropean Journal of CancerVolume 216, 5 February 2025, 115146 Available from:https://doi.org/10.1016/j.ejca.2024.115146

11. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMADermatol 2015;151:1081-1086.Available from:https://doi.org/10.1001/jamadermatol.2015.1187

12. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012;166:1069-1080.Available from:https://doi.org/10.1111/j.1365-2133.2012.10830.x

13. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015;51:1989-2007. Available from:https://doi.org/10.1016/j.ejca.2015.06.110

14. Kauvar AN, Arpey CJ, Hruza G, Olbricht SM, Bennett R, Mahmoud BH. Consensus for nonmelanoma skin cancer treatment, part II: squamous cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg 2015;41:1214-1240. Available from:https://doi.org/10.1097/DSS.0000000000000478

15. A. Sezer, S. Kilickap, M. Gümüş, et al.Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial Lancet, 397 (2021), pp. 592-604Available from:https://doi.org/10.1016/S0140-6736(21)00228-2

16. M. Gogishvili, T. Melkadze, T. Makharadze, et al.Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial Nat Med, 28 (2022), pp. 2374-2380. Available from:https://www.nature.com/articles/s41591-022-01977-y

17. F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin., 68 (2018), pp. 394-424 Available from:https://doi.org/10.3322/caac.21492

18. R. Burk, Z. Chen, C. Saller, T.C.G.A.R. Network Integrated genomic and molecular characterization of cervical cancer Nature, 543 (2017), pp. 378-384. Available from: https://www.nature.com/articles/nature21386

19. M.A. Socinski, C. Obasaju, D. Gandara, et al. Current and emergent therapy options for advanced squamous cell lung cancer J Thorac Oncol, 13 (2018), pp. 165-183 Available from:https://doi.org/10.1016/j.jtho.2017.11.111

20. S.V. Soldera, N.B. Leighl Update on the treatment of metastatic squamous non-small cell lung cancer in New Era of personalized medicine Front Oncol, 7 (2017), p. 50Available from: https://doi.org/10.3389/fonc.2017.00050

Quality in Sport

Downloads

  • PDF

Published

2026-09-28

How to Cite

1.
PIWOWARCZYK, Alicja, BIAŁAS , Julia, PALUCHOWSKA, Joanna, KODURA, Alicja, PIĄTEK, Przemysław, SZYMAŃSKI, Łukasz, MORDARSKA, Milena, MERC, Artur and ŁOZOWSKI, Jan. Cemiplimab in oncology: a review of the literature. Quality in Sport. Online. 28 September 2026. Vol. 77, p. 75787. [Accessed 18 November 2026]. DOI 10.12775/QS.2026.77.75787.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 77 (2026)

Section

Medical Sciences

License

Copyright (c) 2026 Alicja Piwowarczyk, Julia Białas , Joanna Paluchowska, Alicja Kodura, Przemysław Piątek, Łukasz Szymański, Milena Mordarska, Artur Merc, Jan Łozowski

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Stats

Number of views and downloads: 166
Number of citations: 0

Search

Search

Browse

  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

cemiplimab, non-small cell lung cancer, cervical cancer, cutaneous squamous cell carcinoma, PD-1 receptor inhibitor
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop